Good research r042wal, every little bit helps. I did notice again on your chart (I held up to the screen a TA bottom channel finder, a piece of paper, lol) that October and January were the last 2 times APH hit this trend line, both nice bounces. Let's hope this bounce is even bigger and fueled by DIN, branding and, what the heck, a nice juicy Australian contract (with a side of shrimp) straight off the barbi.
I've been in APH since Aug. I missed my sell on the 1.57 pop (would have been nice to get back in around here) so will be looking for a move at least to $2.00. With the right news I think that will just be the start. LT, wow, $4 to $6 are not out of the question when some of their human testing (silly humans) is successful. Speaking of fungus, Novartis (Lamisil)and Schering-Plough (Tinactin, Dr.Scholl's) trade at around $50 and $20 (both off their highs, btw, may be good trade potential). Granted, they are much bigger companies than just their Athlete's foot lines, but Alda has at least as much potential with a very safe and effective product line, not to mention tremendous buy-out potential.
I post on TCC as Dog but always like to keep my ear to the grapevine, good group here.
News 
Market Data 
Discover 
AI
